Next Article in Journal
HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape
Next Article in Special Issue
Sugar Transporter Proteins (STPs) in Gramineae Crops: Comparative Analysis, Phylogeny, Evolution, and Expression Profiling
Previous Article in Journal
gga-miRNA-18b-3p Inhibits Intramuscular Adipocytes Differentiation in Chicken by Targeting the ACOT13 Gene
Previous Article in Special Issue
In Silico Genome-Wide Analysis of Respiratory Burst Oxidase Homolog (RBOH) Family Genes in Five Fruit-Producing Trees, and Potential Functional Analysis on Lignification of Stone Cells in Chinese White Pear
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Silico Analysis of Bioactive Peptides in Invasive Sea Grass Halophila stipulacea

by
Cagin Kandemir-Cavas
1,
Horacio Pérez-Sanchez
2,*,
Nazli Mert-Ozupek
3 and
Levent Cavas
4,*
1
Department of Computer Science, Faculty of Science, Dokuz Eylül University, İzmir 35390, Turkey
2
Bioinformatics and High Performance Computing Research Group (BIO-HPC), Computer Engineering Department, Universidad Católica de Murcia (UCAM), 30107 Murcia, Spain
3
Institute of Oncology, Dokuz Eylül University, İzmir 35320, Turkey
4
Department of Chemistry, Faculty of Science, Dokuz Eylül University, İzmir 35390, Turkey
*
Authors to whom correspondence should be addressed.
Cells 2019, 8(6), 557; https://doi.org/10.3390/cells8060557
Submission received: 4 April 2019 / Revised: 28 May 2019 / Accepted: 30 May 2019 / Published: 7 June 2019
(This article belongs to the Special Issue Bioinformatics and Computational Biology 2019)

Abstract

:
Halophila stipulacea is a well-known invasive marine sea grass in the Mediterranean Sea. Having been introduced into the Mediterranean Sea via the Suez Channel, it is considered a Lessepsian migrant. Although, unlike other invasive marine seaweeds, it has not demonstrated serious negative impacts on indigenous species, it does have remarkable invasive properties. The present in-silico study reveals the biotechnological features of H. stipulacea by showing bioactive peptides from its rubisc/o protein. These are features such as antioxidant and hypolipideamic activities, dipeptidyl peptidase-IV and angiotensin converting enzyme inhibitions. The reported data open up new applications for such bioactive peptides in the field of pharmacy, medicine and also the food industry.

1. Introduction

Invasive species are becoming an important problem in the Mediterranean Sea where many vectors exist, including inflowing water from the Suez Channel and ships’ ballast waters. One of the best-known invasive sea grasses is Halophila stipulacea (Forsskål) Ascherson [1], which was first reported in the Mediterranean Sea by Friscth [2]. This sea grass is abundant in the eastern Mediterranean Basin and very common along the Turkish coastline [3]. No validated eradication method for this invasive species is described in the scientific literature. A few reports mention the negative impacts of H.stipulacea on indigenous species [4], although Willette and Ambrose [5] mention that little is known of H. stipulacea’s effects in its recently discovered Caribbean locations, while Van Tussenbroek et al. [6] report that H.stipulacea may be harmful for native species. Although most efforts so far have been devoted to finding alternative ways of evaluating non-indigenous species [7,8], invasive species secrete interesting secondary metabolites that can be exploited economically under the title of blue biotechnology. Indeed, recent years have seen growing interest in blue biotechnology-based products [9]. For example, bioactive peptides are one of the candidate targets that can be isolated from invasive species. However, to the best of our knowledge, the bioactive peptides from invasive H. stipulacea have not been assessed, and the aim of the present contribution is to fill in this gap in the literature.
Bioactive peptides (hereafter BPs) comprise 3–20 free amino acid food protein fragments [10] composed of covalently bonded (amide/peptide bonds) amino acids [11]. According to the BP database called BIOPEP [12], there are more than 3500 different BPs. The sources of natural BPs can be land-, marine- or food-derived, and include seaweeds [13,14] tropical amphibians [15], cyanobacterium [16], fermented soybean meal [17], sea cucumber [18], cereal crops [19] and milk [20]. BPs are of great importance because of their positive impact on human health. Daliry et al. [21] classified food-derived BPs as anti-cancer, antidiabetic, antihypertensive, antimicrobial, cholesterol-lowering peptides, and multifunctional peptides [21]. Since they help prevent the oxidation and microbial degradation of foods, BPs could be defined as a “new generation” of bioactive regulators [11]. Although BPs are generally coded in the parent protein structure, some BPs are found free in natural sources [11]. Due to their biological and pharmaceutical properties, the production of BPs is of great importance, whether it be by enzymatic hydrolysis [22], chemical synthesis [23] or microbial fermentation [24]. Other production processes include separation and purification techniques such as gel filtration, ultrafiltration [25,26], reverse phase ultra-flow liquid chromatography (RP-UFLC) [25], and reverse phase high performance liquid chromatography (RP-HPLC) and characterization methods such as ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) [27]. Since these production, isolation, purification and characterization protocols are time- and solvent-consuming, bioinformatics tools are increasingly used [13,16]. The role of database-aided bioinformatics tools is to quantitatively predict the structure–activity relationship. Many tools have been developed such as BIOPEP [12], Antimicrobial Peptide Database (APD) [28] and PepBank [29]. Ribulose-1,5-bisphosphate carboxylase/oxygenase (RubisCO, E.C. 4.1.1.39) is an important photosynthetic enzyme and the most abundant protein in the world [14,30]. RubisCO is a bifunctional multimeric enzyme and it plays a role in photorespiration and carbon fixation in the Calvin cycle [19,30]. Thirty to fifty percent of RubisCO is soluble and contains eight large (56 kDa) and eight small (14 kDa) subunits [31]. The small subunits of RubisCO contain high amounts of cationic and hydrophobic amino acids [31], while a bioactive dipeptide (Phe-Cys), which suppresses oxidative stress, has been obtained from the large subunit of RubisCO by in-silico thermolysin hydrolysis [32]. Some RubisCO derived peptides have revealed opioid activity, and some are G-protein coupled receptor ligands which constitute the most important class of drug targets [30]. Although there have been attempts at the chemical analysis of H. stipulacea [33], its detailed chemical composition is still not known in full.
This contribution presents an alternative and sustainable method for evaluating the invasive sea grass H. stipulacea by using in silico analysis of BPs in the large chain of RubisCO. Bioactive peptides are of great importance for the preparation of functional foods because of their excellent health-related effects. Many bioactivities, including antioxidant, antihypertensive and enzyme inhibitory properties have been associated with bioactive peptides from RubisCO of plants [13,19].

2. Materials and Methods

2.1. Sequence of H. stipulacea Rubisc/o

Ribulose bisphosphate carboxylase large chain of H. stipulacea (H6TQS9) was retrieved from the UniProtKB/Swiss-Prot database at the ExPASy Bioinformatics Resource Portal [34]. According to the portal, the sequence provided is a fragment and consists of 200 amino acids.

2.2. In silico BIOPEP Parameters

All in-silico calculations were performed using the codes implemented in the BIOPEP webserver [12]. One of the main theoretical parameters (A) is defined as the frequency of occurrence of bioactive fragments in the protein chain A [12,35,36], which can be calculated by using Equation (1):
A = a / N
where a is the number of fragments with given activity in a protein sequence and N is the number of amino acid residues in the protein chain [12,35,36].
The frequency with which fragments with given activity were released by enzymes (AE) and the relative frequency of release of fragments with given activity by enzymes (W) were calculated based on Equations (2) and (3), respectively.
A E = d / N
where d is the number of fragments with given activity in the protein sequence that could be released by enzymes, and N is the number of amino acid residues in the protein chain. The relative frequency of release of fragments with given activity by selected enzymes (W) is given by:
W = A E / A
The values of AE and A are defined according to Equations (1) and (2), respectively.
Potential biological activity of protein (B) [µM−1]:
B = i = 1 k a i E C 50 i N
In Equation (4), ai is the number of repetitions of the i-th bioactive fragment in protein sequence, EC50i is the concentration of the i-th bioactive peptide corresponding to its half-maximal activity [µM], k is the number of different fragments with given activity and N is the number of amino acid residues [35].
The theoretical degree of hydrolysis (DHt) was also calculated using the following Equation (5):
D H t = d D × 100 %
In Equation (5), d is number of hydrolyzed peptide bonds and D is total number of peptide bonds in a protein chain.
The relative activity of fragments with given activity released by selected enzymes (V) is:
V = B E B
In Equation (6), BE is the activity of fragments potentially released by proteolytic enzyme (enzymes) and B is the potential biological activity of the protein.
The amino acid composition of protein was determined based on protein sequences, using the ProtParam program [37] available at [38].

3. Results

H. stipulacea large chain RubisCO was retrieved from expasy.org. After in silico proteolytic fragmentation of the RubisCO by BIOPEP tools, bioactive peptides were obtained. The raw data can be found in Appendix A (Table A1, Table A2, Table A3, Table A4, Table A5, Table A6, Table A7, Table A8, Table A9, Table A10, Table A11, Table A12, Table A13, Table A14, Table A15, Table A16, Table A17, Table A18, Table A19, Table A20, Table A21, Table A22, Table A23, Table A24, Table A25, Table A26, Table A27, Table A28, Table A29, Table A30, Table A31, Table A32, Table A33, Table A34, Table A35, Table A36, Table A37, Table A38, Table A39, Table A40, Table A41, Table A42, Table A43, Table A44, Table A45, Table A46, Table A47, Table A48, Table A49, Table A50, Table A51, Table A52, Table A53, Table A54, Table A55 and Table A56). BIOPEP parameters (A, AE, W, BHt and V) were extracted from the raw data and the results are presented in the Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9 and Table 10.
The angiotensin-converting enzyme (ACE) inhibitor properties of bioactive peptides from RubisCO of H. stipulacea were given in Table 1. The values were not calculated for prolyl endopeptidase, clostripain, thrombin, glutamyl endopeptidase II, Xaa-dipeptidase, chymosin, ginger protease (zingipain). From this table, maximum and minimum A values were found to be 0.5833 and 0.5808, respectively. The highest values were observed in V-protease, endopeptidase, V-8 protease (Glutamyl endopeptidase), and the minimum values were found in trypsin, plasmin and oligopeptidase B. The maximum AE value was found to be 0.0874 (calpain 2) and the minimum AE values were found to be 0.0097 (plasmin, oligopeptidase B, tripsin). The maximum and minimum relative frequency of release of fragments (W) were found if RubisCO is cleaved by calpain 2 (0.1500) and V-protease, glycyl endopeptidase, V8-protease (glutamyl endopeptidase) (0.0084).
The highest B value was found to be 0.0055 (subtilisin) and the lowest B values were found to be 0 for trypsin, pepsin, plasmin, pancreatic elastase II, oligopeptidase B, glycyl endopeptidase, oligopeptidase F and V-8 protease (Glutamyl endopeptidase). The maximum and minimum V values were found to be 0.2057 and 0.0002, respectively. The maximum value was observed in subtilisin and the minimum value was found in glycyl endopeptidase. ACE is known as dipeptidyl carboxypeptidase and one of its major roles is controlling blood pressure [39]. In the literature, Agirbasli and Cavas [13] evaluated the frequency of occurrence (A) values of ACE inhibitor peptides in Caulerpa RubisCO and found that C. racemosa var. lamourouxii, C. taxifolia and C. racemosa f. occidentalis had the highest A values (0.4330, 0.4330 and 0.3993, respectively) and C. racemosa var. turbinata exhibited the lowest (0.3822). Another study revealed that C. microphysa had potential ACE inhibitory activity as a result of pepsin cleavage [40]. However, the number of bioactive peptides in the BIOPEP database has increased, and so the frequency values might have been altered.
The antioxidative properties of BPs from RubisCO of H. stipulacea are listed in Table 2. Results reveal that maximum and minimum A values were 0.07282 and 0.07280, respectively. The minimum A value was obtained when proteinase K was used as protease. Minimum A values were found in calpain 2 and proteinase P1 (lactocepin). The maximum and minimum AE values were obtained as 0.0243 (proteinase K) and 0.0049 (chmytripsin, cathepsin, chymase, papain, ficin, leukocyte elastase, metridin, bromelain and pepsin), respectively. Proteinase K had the maximum W value (0.3338) and chymase, papain, ficin, leukocyte elastase, metridin, bromelain and pepsin had the lowest W values (0.0673). When thrombin, endopeptidase II, Xaa-Pro dipeptidase, chymosin and ginger protease (zingipain) were used for cleaving, no antioxidative fragment from RubisCO of H. stipulacea was found. The inhibition of lipid peroxidation, scavenging of radicals and metal chelation are among the antioxidative properties of BPs [41]. In the literature, the antioxidative activity of BPs have been evaluated in-silico. According to a recent study, the highest A value for the antioxidative properties of RubisCO was found in Caulerpa taxifolia (0.0785) samples and C. cylindracea (0.0759) species [13]. Also, Udenigwe et al. [19,30] found the maximum and minimum A value of antioxidative properties of RubisCO of cereal crops to be 0.0568 and 0.0464, respectively [19].
The inhibition effects of bioactive peptides from RubisCO of H. stipulacea on dipeptidyl peptidase IV (DPP-IV) (E.C. 3.4.14.5) are given in Table 3. According to the results, prolyl oligopeptidase, V-protease, clostripain and glycyl endopeptidase have the maximum (0.6533) and cathepsin, chymase and metridin have the minimum (0.6497) A value. The maximum AE value was 0.1214 when calpain 2 was used as a protease in DPP-IV inhibitor activity. The minimum AE value (0.0049) was found in prolyl oligopeptidase, V-protease, clostripain and glycyl endopeptidase. Calpain 2 had the maximum (0.1866) and prolyl oligopeptidase, V-protease and clostripain had the minimum (0.0075) W value. We found very low B values for all the enzymes studied. The highest V value was found in pepsin (pH > 2) (0.4569), while tripsin, prolyl oligopeptidase, V8-protease, plasmin, clostripain, oligopeptidase B, glycyl endopeptidase and proteinase P1 had the lowest V value (0.0000). DPP-IV is crucial in glucose metabolism and it degrades the incretins [42]. Thus, DPP-IV inhibitors play a major role in type-2 diabetes mellitus in which insulin secretion and blood glucose level stability are of great importance. [42]. Agirbasli and Cavas found the A value of DPP-IV to be between 0.0550 and 0.0714 in all of Caulerpa species [13]. They also mentioned that caulerpenyne is found in Caulerpa species and its alpha-amylase inhibition activity may play an important role in reducing starch degradation. In another in silico study carried out by Udenigwe et al. [19,30], rice and oat showed the highest A value (0.0758).
Table 4 shows the ubiquitin-mediated proteolysis (UbMP) activating properties of bioactive peptides from RubisCO of H. stipulacea. The A value was 0.0146 in pancreatic elastase, leukocyte elastase, proteinase P1 (lactocepin) and pepsin (pH > 2). The maximum AE value was 0.0097 (pancreatic elestase) and the minimum AE values were 0.0049 for leukocyte elastase and proteinase P1. Also, when thrombin, endopeptidase II and Xaa-Pro dipeptidase, chymosin and ginger protease were used, a ubiquitin-mediated proteolysis fragment from H. stipulacea was not found. Pancreatic elastase and pepsin have the highest W value (0.6644) and leukocyte elastase and proteinase P1 have the lowest W value (0.3356). No B or W value was found for UbMP properties of bioactive peptides from RubisCO of H. stipulacea. UbMP is crucial for brain development [43] and its absence causes neurodegenerative diseases such as Parkinson’s and Alzheimer’s [44]. In the literature, Minkiewicz et al. [36] carried out an in-silico evaluation of bovine meat proteins and found that the highest A value of activating UbMP was 0.028 in tropomyosin α-1 chain [36].
Results for bioactive regulating fragments from H. stipulacea by proteases are shown in Table 5. The results reveal that the only A value (0.0146) was found in chymotrypsin, ficin, calpain 2 and pepsin. The maximum AE value (0.0049) was obtained in chymotrypsin, ficin, calpain 2 and pepsin. Chymotrypsin, ficin, calpain 2 and pepsin had the same W values (0.3356). B and V values were not found for the bioactive regulating activity of H. stipulacea by proteases.
Table 6 shows the antithrombotic activity of BPs from H. stipulacea. According to the results, maximum A, AE and W values (0.0097, 0.0049 and 0.5052, respectively) were obtained for chymotrypsin, calpain 2 and pepsin. The B and V values of the antithrombotic properties of H. stipulacea by proteases were not found. Antithrombic activity is essential for the reduction of thrombin. In the study of Agirbasli and Cavas [13], the A values of antithrombic activity of BPs from Caulerpa genus were found within the range of 0.0010 to 0.0100 [13].
The antiamnestic activity values of the bioactive peptides are given in Table 7. The only A value found (0.0097) was found in chymotrypsin, calpain 2 and pepsin. Also, the maximum AE and W values (0.0049 and 0.5052, respectively) were obtained by chymotrypsin, calpain 2 and pepsin. Agirbasli and Cavas [13] found the A values of antiamnestic activity of BPs from Caulerpa genus to be within the range of 0.0010 to 0.0100, the same as for antihrombic activity, perhaps because they act in the similar pathway way [13].
The results of stimulating fragments of H. stipulacea are given in Table 8. The highest A, AE and W values (0.0340, 0.0049 and 0.1441) were obtained by papain and pepsin (pH > 2).
Table 9 provides the immunomodulating activity results of BPs from H. stipulacea. The results reveal that calpain 2 has the highest A, AE and W values (0.0097, 0.0049 and 0.5052, respectively). It is interesting to note A, AE, W, B or V values could not be calculated for other enzymes in this study.
In Table 10, the theoretical degree of hydrolysis (DHt) are given for the following proteases: Chymotrypsin A, trypsin, pepsin, proteinase K, pancreatic elastase, prolyl oligopeptidase, V8-protease, thermolysin, chymotrypsin C, plasmin, cathepsin, clostripain, chymase, papain, ficin, leukocyte elastase, metridin, thrombin, pancreatic elastase II, bromelain, endopeptidase II, oligopeptidase B, calpain 2, glycyl endopeptidase, oligopeptidase F, proteinase P1 (lactocepin), Xaa-Pro dipeptidase, pepsin (pH > 2), cocolysin, subtilisin, chymosin, ginger protease (zingipain) and V-8 protease (Glutamyl endopeptidase). According to the results, the highest and the lowest DHt values were found in pepsin pH > 2 (70.7317) and thrombine, endopeptidase II, Xaa-Pro dipeptidase, chymocine, ginger protease (0), respectively.
In-silico analysis is regarded as an important tool by food scientists since in-silico results may reflect in-vitro and in-vivo results [10,45,46,47,48]. Lafarga et al. [48] defined new bioactive peptides that show ACE and DPP IV inhibition. They confirmed their biological activity by synthetic tripeptides. Sayd et al. [49] also used a similar strategy, grouping the bioactive meat proteins into three categories based on their digestion dynamic. In recent years, there has been a growth in meat consumption as a result of an increasing population. This demand may increase the use of growth hormones, which, in some countries, are banned, but in others allowed [50]. Therefore, an alternative protein source to meat would be of great interest. In this respect, marine seaweeds and seagrasses can be exploited on an industrial scale since there is no hormone ingredient.

4. Discussion

Blue biotechnology and blue growth have become two of the hottest topics in recent years. The evaluation of invasive species may open up a new door in the search for novel agents such as vaccines, secondary metabolites and medicines. The present paper reveals that H.stipulacea contains bioactive peptides. These peptides can be harvested and evaluated in the countries affected. However, any possible industrial collection of H.stipulacea would have to be approved by local authorities. Since H.stipulacea forms a mixed vegetation with local Mediterranean macrophytes and seaweeds, its uncontrolled collection might damage the local species. In conclusion, invasive species in the Mediterranean Sea contain very important secondary metabolites and bioactive peptides. Instead of applying blunt eradication methods, biotechnological evaluation is needed.

Author Contributions

Conceptualization, L.C. and H.P.-S.; methodology, L.C.; software, C.K.-C., N.M.-O.; validation, C.K.-C., N.M.-O.; formal analysis, L.C. and H.P.-S.; investigation, L.C. and H.P.-S.; resources, L.C. and H.P.-S.; data curation, C.K.-C., N.M.-O.; writing—original draft preparation, L.C. and C.K.-C., N.M.O.; writing—review and editing, L.C., C.K.-C. and H.P.-S.; visualization, L.C., C.K.-C.; supervision, L.C., and H.P.-S.; project administration, L.C. and H.P.-S.; funding acquisition, L.C. and H.P.-S.

Funding

This project was financially supported by Turkish Higher Education Council (YÖK) under Mevlana-Project Based Academic Exchange Programme (MEV-2017-230) and by grants from the Spanish Ministry of Economy and Competitiveness (CTQ2017-87974-R) and by the Fundación Séneca del Centro de Coordinación de la Investigación de la Región de Murcia under Projects 20988/PI/18 and 20524/PDC/18.

Acknowledgments

This project was financially supported by Turkish Higher Education Council (YÖK) under Mevlana-Project Based Academic Exchange Programme (MEV-2017-230) and by grants from the Spanish Ministry of Economy and Competitiveness (CTQ2017-87974-R) and by the Fundación Séneca del Centro de Coordinación de la Investigación de la Región de Murcia under Projects 20988/PI/18 and 20524/PDC/18.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A. (Raw Data)

Table A1. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using chymotripsine.
Table A1. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using chymotripsine.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
23384VF(128–129)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor264.1360264.3100
33546VAY(103–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor351.1680351.3820
47513PL(106–107)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
57591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
67599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
77691KY(168–169)ACE inhibitor from wakameACE inhibitor309.1570309.3440
87693KL(21–22)ACE inhibitor from wakameACE inhibitor259.1780259.3340
98219TY(23–24)antioxidative peptideantioxidative282.1100282.2750
108561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
118638PL(106–107)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
128782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
138819KY(168–169)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor309.1570309.3440
148886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
158914TY(23–24)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor282.1100282.2750
168917VF(128–129)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor264.1360264.3100
179071IAY(100–102)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor365.1840365.4090
189074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A2. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using chymotripsin.
Table A2. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using chymotripsin.
DHt (%)
23.4146
No.ActivityAEWBEV
1ACE inhibitor0.04850.08330.00172613144348530.06450702174869
2antioxidative0.00490.067300
3dipeptidyl peptidase IV inhibitor0.03400.05231.8563339357632E-60.0086054864513139
Table A3. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using trypsine.
Table A3. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using trypsine.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
17603GR(84–85)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor231.1220231.2400
27697YK(82–83)ACE inhibitor from wakameACE inhibitor309.1570309.3440
38769DR(164–165)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
48858PK(180–181)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1460243.2910
58939YK(82–83)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor309.1570309.3440
Table A4. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using trypsine.
Table A4. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using trypsine.
DHt (%)
10.7317
No.ActivityAEWBEV
1ACE inhibitor0.00970.01679.4749721470635E-60.00035408788633428
2dipeptidyl peptidase IV inhibitor0.01460.022400
Table A5. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pepsin.
Table A5. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pepsin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
27591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
37599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
48561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
58782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
68886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
79074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A6. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using pepsin.
Table A6. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using pepsin.
DHt (%)
12.1951
No.ActivityAEWBEV
1ACE inhibitor0.01940.03332.5006640432763E-50.00093451973448837
2dipeptidyl peptidase IV inhibitor0.01460.02241.8563339357632E-60.0086054864513139
Table A7. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using proteinase K.
Table A7. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using proteinase K.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
23378GRP(170–172)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor328.1740328.3570
33563AY(101–102)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor252.1000252.2490
43563AY(104–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor252.1000252.2490
53563AY(147–148)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor252.1000252.2490
67591GF(12–13)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
77591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
87599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
97608GV(47–48)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
107693KL(21–22)ACE inhibitor from wakameACE inhibitor259.1780259.3340
117693KL(181–182)ACE inhibitor from wakameACE inhibitor259.1780259.3340
127752EY(28–29)ACE inhibitor from shark meat hydrolysateInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor310.1050310.2860
137810KP(179–180)ACE inhibitor from anchovy and bonitoInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor243.1460243.2910
147866AY(101–102)peptide from Okara proteinPeptide obtained by hydrolysis of Okara protein by use of enzymatic preparation Protease N.antioxidative252.1000252.2490
157866AY(104–105)peptide from Okara proteinPeptide obtained by hydrolysis of Okara protein by use of enzymatic preparation Protease N.antioxidative252.1000252.2490
167866AY(147–148)peptide from Okara proteinPeptide obtained by hydrolysis of Okara protein by use of enzymatic preparation Protease N.antioxidative252.1000252.2490
178218KP(179–180)Antioxidative peptideFree radical scavengerantioxidative243.1460243.2910
188219TY(23–24)antioxidative peptideantioxidative282.1100282.2750
198503TP(26–27)Dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor216.0990216.2220
208505SP(2–3)Dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.0840202.1970
218505SP(43–44)Dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.0840202.1970
228519KP(179–180)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1460243.2910
238529EP(90–91)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor244.0940244.2330
248532QP(45–46)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1100243.2480
258561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
268765AY(101–102)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor252.1000252.2490
278765AY(104–105)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor252.1000252.2490
288765AY(147–148)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor252.1000252.2490
298777EY(28–29)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor310.1050310.2860
308782GF(12–13)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
318782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
328786GV(47–48)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
338793HI(88–89)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor268.1420268.3020
348879QV(160–161)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1260245.2640
358884RI(143–144)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
368886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
378914TY(23–24)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor282.1100282.2750
389073TP(26–27)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor216.0990216.2220
399074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
409146QGP(153–155)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor300.1310300.3000
Table A8. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by proteinase K.
Table A8. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by proteinase K.
DHt (%)
37.0732
No.ActivityAEWBEV
1ACE inhibitor0.07770.13340.00331887346989320.12402916586194
2antioxidative0.02430.333800
3dipeptidyl peptidase IV inhibitor0.09220.14177.4392944998736E-60.034486655009987
Table A9. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pancreatic elastase.
Table A9. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pancreatic elastase.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13174KA(8–9)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor217.1310217.2530
23257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
34005RA(135–136)Activation of ubiquitin-dependent proteolysisactivating ubiquitin-mediated proteolysis245.1380245.2670
44005RA(193–194)Activation of ubiquitin-dependent proteolysisactivating ubiquitin-mediated proteolysis245.1380245.2670
57513PL(106–107)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
67588RA(135–136)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor245.1380245.2670
77588RA(193–194)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor245.1380245.2670
87604KG(83–84)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1; MEROPS ID: XM02-001)ACE inhibitor203.1150203.2260
97605FG(129–130)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
107681DG(74–75)ACE inhibitor from soyInhibitor of Angiotensin-converting enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor190.0479190.1410
117693KL(21–22)ACE inhibitor from wakameACE inhibitor259.1780259.3340
127743KA(8–9)ACE inhibitorInhibitor of angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor217.1310217.2530
138526RA(135–136)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1380245.2670
148526RA(193–194)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1380245.2670
158638PL(106–107)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
168685WT(68–69)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
178685WT(72–73)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
188774ET(6–7)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor248.0890248.2210
198774ET(30–31)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor248.0890248.2210
208793HI(88–89)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor268.1420268.3020
218810KG(83–84)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor203.1150203.2260
228816KT(150–151)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor247.1410247.2790
238851NV(127–128)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor231.1109231.2370
248879QV(160–161)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1260245.2640
258882RG(200–201)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor231.1220231.2400
268884RI(143–144)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
278886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
Table A10. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by pancreatic elastase.
Table A10. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by pancreatic elastase.
DHt (%)
54.6341
No.ActivityAEWBEV
1dipeptidyl peptidase IV inhibitorinhibitor0.07770.11942.0912653098933E-50.096945678488557
2ACE inhibitor0.04370.0750 0.00068578790286240.025628485786464
3activating ubiquitin-mediated proteolysis0.00970.66440
Table A11. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using prolyl oligopeptidase.
Table A11. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using prolyl oligopeptidase.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
18532QP(45–46)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1100243.2480
Table A12. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by prolyl oligopeptidase.
Table A12. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by prolyl oligopeptidase.
DHt (%)
6.8293
No.ActivityAEWBEV
1dipeptidyl peptidase IV inhibitor0.00490.007500
Table A13. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using V-protease.
Table A13. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using V-protease.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
18934YE(29–30)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor310.1050310.2860
29078YE(29–30)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor310.1050310.2860
Table A14. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by V-protease.
Table A14. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by V-protease.
DHt (%)
7.3171
No.ActivityAEWBEV
1dipeptidyl peptidase IV inhibitor0.00490.007500
2ACE inhibitor0.00490.00847.6943555746376E-60.0002875447082947
Table A15. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using thermolysin.
Table A15. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using thermolysin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13522IPP(144–146)ACE inhibitor (from bovine b-CN)ACE inhibitor325.1880325.3940
23666YP(105–106)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor278.1150278.2870
37592FR(40–41)ACE inhibitorACE inhibitor321.1690321.3650
47594VG(11–12)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
57600AG(9–10)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
67600AG(15–16)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
77600AG(53–54)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
87605FG(129–130)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
97619LG(182–183)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
107697YK(20–21)ACE inhibitor from wakameACE inhibitor309.1570309.3440
117859IEP(89–91)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor357.1780357.3930
128521YP(105–106)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor278.1150278.2870
138760AG(9–10)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
148760AG(15–16)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
158760AG(53–54)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
168779FQ(13–14)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor293.1260293.3080
178780FR(40–41)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor321.1690321.3650
188805IQ(159–160)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor259.1420259.2910
198824LT(22–23)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor232.1310232.2650
208918VG(11–12)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
218937YH(87–88)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor318.1210318.3120
228939YK(20–21)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor309.1570309.3440
239076FQ(13–14)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor293.1260293.3080
249087YH(87–88)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor318.1210318.3120
259213LR(134–135)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor287.1850287.3480
269213LR(137–138)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor287.1850287.3480
279213LR(142–143)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor287.1850287.3480
Table A16. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by thermolysin.
Table A16. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by thermolysin.
DHt (%)
36.5854
No.ActivityAEWBEV
1ACE inhibitor0.07770.13340.00517002078075550.19320813846713
2dipeptidyl peptidase IV inhibitor0.05340.08211.5313466662583E-60.0070989290961449
Table A17. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using Chymotrypsin.
Table A17. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using Chymotrypsin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
12753GP(154–155)peptide regulating the stomach mucosal membrane activityregulating the stomach mucosal membrane activityregulating172.0730172.1690
23169GP(154–155)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor172.0730172.1690
33257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
43283GP(154–155)antithromboticantithrombotic172.0730172.1690
53378GRP(170–172)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor328.1740328.3570
63461GP(154–155)Prolyl endopeptidase inhibitorInhibitor of Prolyl Endopeptidase (PEP) (EC 3.4.21.26) (MEROPS ID: S09.001)antiamnestic172.0730172.1690
73546VAY(103–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor351.1680351.3820
83563AY(147–148)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor252.1000252.2490
97512GP(154–155)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor172.0730172.1690
107599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
117691KY(168–169)ACE inhibitor from wakameACE inhibitor309.1570309.3440
127693KL(21–22)ACE inhibitor from wakameACE inhibitor259.1780259.3340
137693KL(181–182)ACE inhibitor from wakameACE inhibitor259.1780259.3340
147829VE(161–162)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor246.1100246.2490
157830TE(5–6)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor248.0890248.2210
167866AY(147–148)peptide from Okara proteinPeptide obtained by hydrolysis of Okara protein by use of enzymatic preparation Protease N.antioxidative252.1000252.2490
178219TY(23–24)antioxidative peptideantioxidative282.1100282.2750
188503TP(26–27)Dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor216.0990216.2220
198505SP(2–3)Dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.0840202.1970
208561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
218765AY(147–148)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor252.1000252.2490
228819KY(168–169)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor309.1570309.3440
238886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
248899TE(5–6)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor248.0890248.2210
258914TY(23–24)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor282.1100282.2750
268916VE(161–162)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor246.1100246.2490
279071IAY(100–102)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor365.1840365.4090
289073TP(26–27)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor216.0990216.2220
Table A18. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by Chymotrypsin.
Table A18. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by Chymotrypsin.
DHt (%)
35.6098
No.ActivityAEWBEV
1regulating0.00490.33560
2dipeptidyl peptidase IV inhibitor0.04850.07465.217325115104E-60.024186176702991
3ACE inhibitor0.06310.10830.00179519628984860.067088034662415
4antithrombotic0.00490.50520
5antiamnestic0.00490.50520
6antioxidative0.00970.133200
Table A19. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using plasmin.
Table A19. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using plasmin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
17603GR(84–85)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor231.1220231.2400
27697YK(82–83)ACE inhibitor from wakameACE inhibitor309.1570309.3440
38769DR(164–165)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
48858PK(180–181)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1460243.2910
58939YK(82–83)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor309.1570309.3440
Table A20. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by plasmin.
Table A20. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by plasmin.
DHt (%)
10.7317
No.ActivityAEWBEV
1ACE inhibitor0.00970.01679.4749721470635E-60.00035408788633428
2dipeptidyl peptidase IV inhibitor0.01460.022400
Table A21. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using cathepsin.
Table A21. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using cathepsin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
23546VAY(103–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor351.1680351.3820
37513PL(106–107)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
47591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
57599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
67693KL(21–22)ACE inhibitor from wakameACE inhibitor259.1780259.3340
78219TY(23–24)antioxidative peptideantioxidative282.1100282.2750
88561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
98638PL(106–107)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
108782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
118886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
128914TY(23–24)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor282.1100282.2750
139071IAY(100–102)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor365.1840365.4090
149074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A22. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by cathepsin.
Table A22. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by cathepsin.
DHt (%)
20.4878
No.ActivityAEWBEV
1ACE inhibitor0.03880.06660.000825069651752370.030833564947006
2antioxidative0.00490.067300
3dipeptidyl peptidase IV inhibitor0.02430.03741.8563339357632E-60.0086054864513139
Table A23. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using clostripain.
Table A23. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using clostripain.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
18769DR(164–165)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
Table A24. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by clostripain.
Table A24. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by clostripain.
DHt (%)
5.3659
No.ActivityAEWBEV
1dipeptidyl peptidase IV inhibitor0.00490.007500
Table A25. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using chymase.
Table A25. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using chymase.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
23546VAY(103–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor351.1680351.3820
37513PL(106–107)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
47591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
57599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
67693KL(21–22)ACE inhibitor from wakameACE inhibitor259.1780259.3340
78219TY(23–24)antioxidative peptideantioxidative282.1100282.2750
88561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
98638PL(106–107)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
108782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
118886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
128914TY(23–24)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor282.1100282.2750
139071IAY(100–102)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor365.1840365.4090
149074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A26. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by chymase.
Table A26. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by chymase.
DHt (%)
19.5122
No.ActivityAEWBEV
1ACE inhibitor0.03880.06660.000825069651752370.030833564947006
2antioxidative0.00490.067300
3dipeptidyl peptidase IV inhibitor0.02430.03741.8563339357632E-60.0086054864513139
Table A27. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using papain.
Table A27. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using papain.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13351EEE(95–97)Stimulating vasoactive substance releasestimulating405.1260405.3480
23522IPP(144–146)ACE inhibitor (from bovine b-CN)ACE inhibitor325.1880325.3940
33538VSP(42–44)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor301.1520301.3300
47513PL(172–173)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
57583AF(39–40)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor236.1050236.2560
67594VG(11–12)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
77600AG(9–10)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
87600AG(15–16)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
97600AG(53–54)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
107600AG(93–94)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
117617QG(153–154)ACE inhibitorACE inhibitor203.0790203.1830
127681DG(74–75)ACE inhibitor from soyInhibitor of Angiotensin-converting enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor190.0479190.1410
137951YYT(24–26)synthetic peptideantioxidative445.1730445.4450
148559AL(133–134)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.1210202.2390
158559AL(136–137)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.1210202.2390
168560SL(78–79)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor218.1160218.2400
178638PL(172–173)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
188685WT(68–69)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
198759AF(39–40)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor236.1050236.2560
208760AG(9–10)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
218760AG(15–16)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
228760AG(53–54)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
238760AG(93–94)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
248764AV(56–57)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
258769DR(80–81)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
268769DR(164–165)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
278774ET(6–7)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor248.0890248.2210
288871QG(153–154)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor203.0790203.1830
298878QT(4–5)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor247.1050247.2360
308918VG(11–12)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
318951AV(56–57)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
329074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A28. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using papain.
Table A28. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using papain.
DHt (%)
43.4146
No.ActivityAEWBEV
1stimulating0.00490.14410
2ACE inhibitor0.06310.10830.00192219670907350.071834149934202
3antioxidative0.00490.067300
4dipeptidyl peptidase IV inhibitor0.08250.12682.3003804384162E-50.10663971774841
Table A29. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using ficin.
Table A29. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using ficin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
12749DY(19–20)ion flow regulating peptideion flow regulating peptideregulating296.0899296.2590
23546VAY(103–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor351.1680351.3820
37513PL(106–107)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
47513PL(172–173)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
57558VK(17–18)ACE inhibitor from buckwheatACE inhibitor245.1620245.3070
67594VG(11–12)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
77600AG(9–10)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
87617QG(153–154)ACE inhibitorACE inhibitor203.0790203.1830
97621TG(65–66)ACE inhibitorACE inhibitor176.0680176.1570
107682NY(190–191)ACE inhibitor from garlicACE inhibitor295.1059295.2740
117698NK(167–168)ACE inhibitor from wakameACE inhibitor260.1369260.2780
128185TF(151–152)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor266.1150266.2820
138219TY(23–24)antioxidative peptideantioxidative282.1100282.2750
148559AL(133–134)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.1210202.2390
158559AL(136–137)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.1210202.2390
168638PL(106–107)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
178638PL(172–173)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
188760AG(9–10)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
198769DR(80–81)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
208769DR(164–165)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
218853NY(190–191)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor295.1059295.2740
228858PK(180–181)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1460243.2910
238871QG(153–154)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor203.0790203.1830
248900TF(151–152)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor266.1150266.2820
258901TG(65–66)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor176.0680176.1570
268910TS(77–78)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor206.0790206.1850
278910TS(120–121)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor206.0790206.1850
288914TY(23–24)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor282.1100282.2750
298918VG(11–12)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
308921VK(17–18)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1620245.3070
318926VS(42–43)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor204.1000204.2130
329071IAY(100–102)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor365.1840365.4090
339072DY(19–20)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor296.0899296.2590
349074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A30. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using ficin.
Table A30. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using ficin.
DHt (%)
44.3902
No.ActivityAEWBEV
1regulating0.00490.33560
2ACE inhibitor0.06800.11670.0015851677235560.059239085878814
3antioxidative0.00490.067300
4dipeptidyl peptidase IV inhibitor0.08740.13441.1006017099609E-50.051021063187465
Table A31. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using leukocyte elastase.
Table A31. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using leukocyte elastase.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13174KA(8–9)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor217.1310217.2530
23257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
34005RA(135–136)Activation of ubiquitin-dependent proteolysisactivating ubiquitin-mediated proteolysis245.1380245.2670
47588RA(135–136)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor245.1380245.2670
57598GA(54–55)ACE inhibitorACE inhibitor146.0580146.1310
67599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
77608GV(10–11)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
87608GV(16–17)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
97612GT(66–67)ACE inhibitorACE inhibitor176.0680176.1570
107743KA(8–9)ACE inhibitorInhibitor of angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor217.1310217.2530
117951YYT(24–26)synthetic peptideantioxidative445.1730445.4450
128524GA(54–55)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
138526RA(135–136)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1380245.2670
148561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
158685WT(68–69)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
168685WT(72–73)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
178774ET(6–7)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor248.0890248.2210
188786GV(10–11)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
198786GV(16–17)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
208816KT(150–151)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor247.1410247.2790
218879QV(160–161)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1260245.2640
228884RI(143–144)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
238886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
248945YS(148–149)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor268.0950268.2500
258946YV(102–103)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor280.1310280.3030
269056DGL(74–76)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor303.1319303.3010
279077YV(102–103)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.1310280.3030
Table A32. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using leukocyte elastase.
Table A32. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using leukocyte elastase.
DHt (%)
38.5366
No.ActivityAEWBEV
1dipeptidyl peptidase IV inhibitor0.07280.11192.2768987034696E-50.10555116493987
2ACE inhibitor0.04850.08330.00245081461731480.091589057379035
3activating ubiquitin-mediated proteolysis0.00490.33560
4antioxidative0.00490.067300
Table A33. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using metridin.
Table A33. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using metridin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
23546VAY(103–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor351.1680351.3820
37513PL(106–107)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
47591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
57599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
67693KL(21–22)ACE inhibitor from wakameACE inhibitor259.1780259.3340
78219TY(23–24)antioxidative peptideantioxidative282.1100282.2750
88561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
98638PL(106–107)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
108782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
118886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
128914TY(23–24)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor282.1100282.2750
139071IAY(100–102)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor365.1840365.4090
149074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A34. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using metridin.
Table A34. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using metridin.
DHt (%)
19.5122
No.ActivityAEWBEV
1ACE inhibitor0.03880.06660.000825069651752370.030833564947006
2antioxidative0.00490.067300
3dipeptidyl peptidase IV inhibitor0.02430.03741.8563339357632E-60.0086054864513139
Table A35. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pancreatic elastase II.
Table A35. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pancreatic elastase II.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
27591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
37599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
48561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
58782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
68886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
79074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A36. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pancreatic elastase II.
Table A36. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pancreatic elastase II.
DHt (%)
13.1707
No.ActivityAEWBEV
1ACE inhibitor0.01940.03332.5006640432763E-50.00093451973448837
2dipeptidyl peptidase IV inhibitor0.01460.02241.8563339357632E-60.0086054864513139
Table A37. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using stem bromelain.
Table A37. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using stem bromelain.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13174KA(8–9)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor217.1310217.2530
23174KA(132–133)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor217.1310217.2530
37513PL(172–173)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
47617QG(153–154)ACE inhibitorACE inhibitor203.0790203.1830
57681DG(74–75)ACE inhibitor from soyInhibitor of Angiotensin-converting enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor190.0479190.1410
67743KA(8–9)ACE inhibitorInhibitor of angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor217.1310217.2530
77743KA(132–133)ACE inhibitorInhibitor of angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor217.1310217.2530
87951YYT(24–26)synthetic peptideantioxidative445.1730445.4450
98638PL(172–173)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
108685WT(68–69)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
118685WT(72–73)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
128769DR(80–81)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
138769DR(164–165)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
148774ET(6–7)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor248.0890248.2210
158816KT(150–151)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor247.1410247.2790
168851NV(127–128)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor231.1109231.2370
178867QA(14–15)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor217.0950217.2100
188871QG(153–154)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor203.0790203.1830
198945YS(148–149)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor268.0950268.2500
208946YV(102–103)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor280.1310280.3030
219074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
229077YV(102–103)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.1310280.3030
Table A38. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using stem bromelain.
Table A38. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using stem bromelain.
DHt (%)
54.1463
No.ActivityAEWBEV
1dipeptidyl peptidase IV inhibitor0.06800.10452.1686874619195E-50.10053477023254
2ACE inhibitor0.03400.05840.000739730773670930.027644377422971
3antioxidative0.00490.067300
Table A39. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using oligopeptidase B.
Table A39. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using oligopeptidase B.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
17603GR(84–85)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor231.1220231.2400
27697YK(82–83)ACE inhibitor from wakameACE inhibitor309.1570309.3440
38769DR(164–165)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
48858PK(180–181)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1460243.2910
58939YK(82–83)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor309.1570309.3440
Table A40. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using oligopeptidase B.
Table A40. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using oligopeptidase B.
DHt (%)
10.7317
No.ActivityAEWBEV
1ACE inhibitor0.00970.01679.4749721470635E-60.00035408788633428
2dipeptidyl peptidase IV inhibitor0.01460.022400
Table A41. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using calpain 2.
Table A41. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using calpain 2.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
12754PG(46–47)peptide regulating the stomach mucosal membrane activityregulating the stomach mucosal membrane activityregulating172.0730172.1690
22882YG(169–170)Immunostimulating peptideEnhancing protein biosynthesis in lymphocytesimmunomodulating238.0840238.2220
33285PG(46–47)Antithrombotic peptideAntithromboticantithrombotic172.0730172.1690
43460PG(46–47)Prolyl endopeptidase inhibitorInhibitor of Prolyl Endopeptidase (PEP) (EC 3.4.21.26) (MEROPS ID: S09.001)antiamnestic172.0730172.1690
53522IPP(144–146)ACE inhibitor (from bovine b-CN)ACE inhibitor325.1880325.3940
63553YG(169–170)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor238.0840238.2220
73563AY(147–148)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor252.1000252.2490
87513PL(172–173)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
97558VK(17–18)ACE inhibitor from buckwheatACE inhibitor245.1620245.3070
107594VG(11–12)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
117600AG(9–10)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
127600AG(15–16)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
137600AG(53–54)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
147600AG(93–94)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
157625PG(46–47)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor172.0730172.1690
167681DG(74–75)ACE inhibitor from soyInhibitor of Angiotensin-converting enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor190.0479190.1410
177697YK(82–83)ACE inhibitor from wakameACE inhibitor309.1570309.3440
187698NK(167–168)ACE inhibitor from wakameACE inhibitor260.1369260.2780
197866AY(147–148)peptide from Okara proteinPeptide obtained by hydrolysis of Okara protein by use of enzymatic preparation Protease N.antioxidative252.1000252.2490
207951YYT(24–26)synthetic peptideantioxidative445.1730445.4450
218559AL(133–134)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.1210202.2390
228559AL(136–137)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.1210202.2390
238560SL(78–79)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor218.1160218.2400
248638PL(172–173)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
258685WT(68–69)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
268760AG(9–10)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
278760AG(15–16)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
288760AG(53–54)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
298760AG(93–94)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
308764AV(56–57)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
318765AY(147–148)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor252.1000252.2490
328769DR(80–81)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
338769DR(164–165)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor289.1279289.2770
348774ET(6–7)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor248.0890248.2210
358779FQ(13–14)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor293.1260293.3080
368779FQ(152–153)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor293.1260293.3080
378805IQ(159–160)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor259.1420259.2910
388855PG(46–47)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor172.0730172.1690
398858PK(180–181)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1460243.2910
408894SK(149–150)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor233.1260233.2540
418918VG(11–12)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
428921VK(17–18)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1620245.3070
438936YG(169–170)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor238.0840238.2220
448938YI(99–100)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor294.1470294.3300
458939YK(82–83)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor309.1570309.3440
468951AV(56–57)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
479076FQ(13–14)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor293.1260293.3080
489076FQ(152–153)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor293.1260293.3080
499184ST(64–65)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor206.0790206.1850
Table A42. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using calpain 2.
Table A42. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using calpain 2.
DHt (%)
47.3171
No.ActivityAEWBEV
1regulating0.00490.33560
2immunomodulating0.00490.50520
3antithrombotic0.00490.50520
4antiamnestic0.00490.50520
5ACE inhibitor0.08740.15000.00343736442200090.12845727500362
6antioxidative0.00970.133200
7dipeptidyl peptidase IV inhibitor0.12140.18662.3003804384162E-50.10663971774841
Table A43. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using glycyl endopeptidase.
Table A43. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using glycyl endopeptidase.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
17594VG(11–12)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
28918VG(11–12)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
Table A44. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using glycyl endopeptidase.
Table A44. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using glycyl endopeptidase.
DHt (%)
9.7561
No.ActivityAEWBEV
1ACE inhibitor0.00490.00844.4130626654898E-60.00016491996042102
2dipeptidyl peptidase IV inhibitor0.00490.007500
Table A45. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using oligopeptidase F.
Table A45. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using oligopeptidase F.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
27591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
37599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
48561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
58782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
68886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
79074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A46. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using oligopeptidase F.
Table A46. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using oligopeptidase F.
DHt (%)
12.1951
No.ActivityAEWBEV
1ACE inhibitor0.01940.03332.5006640432763E-50.00093451973448837
2dipeptidyl peptidase IV inhibitor0.01460.02241.8563339357632E-60.0086054864513139
Table A47. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using proteinase P1 (lactocepin).
Table A47. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using proteinase P1 (lactocepin).
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13563AY(104–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor252.1000252.2490
23563AY(147–148)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor252.1000252.2490
34005RA(135–136)Activation of ubiquitin-dependent proteolysisactivating ubiquitin-mediated proteolysis245.1380245.2670
47588RA(135–136)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor245.1380245.2670
57591GF(12–13)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
67608GV(47–48)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
77866AY(104–105)peptide from Okara proteinPeptide obtained by hydrolysis of Okara protein by use of enzymatic preparation Protease N.antioxidative252.1000252.2490
87866AY(147–148)peptide from Okara proteinPeptide obtained by hydrolysis of Okara protein by use of enzymatic preparation Protease N.antioxidative252.1000252.2490
98526RA(135–136)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1380245.2670
108765AY(104–105)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor252.1000252.2490
118765AY(147–148)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor252.1000252.2490
128782GF(12–13)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
138786GV(47–48)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
148884RI(143–144)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
158895SV(114–115)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor204.1000204.2130
Table A48. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using proteinase P1 (lactocepin).
Table A48. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using proteinase P1 (lactocepin).
DHt (%)
41.4634
No.ActivityAEWBEV
1ACE inhibitor0.02430.04170.000530299824416820.019817762103858
2activating ubiquitin-mediated proteolysis0.00490.33560
3antioxidative0.00970.133200
4dipeptidyl peptidase IV inhibitor0.03400.052300
Table A49. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pepsin (pH >2).
Table A49. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using pepsin (pH >2).
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
12754PG(46–47)peptide regulating the stomach mucosal membrane activityregulating the stomach mucosal membrane activityregulating172.0730172.1690
23172VA(57–58)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
33172VA(92–93)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
43172VA(103–104)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
53257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
63257RL(165–166)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
73285PG(46–47)Antithrombotic peptideAntithromboticantithrombotic172.0730172.1690
83380RY(81–82)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor337.1640337.3580
93384VF(128–129)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor264.1360264.3100
103460PG(46–47)Prolyl endopeptidase inhibitorInhibitor of Prolyl Endopeptidase (PEP) (EC 3.4.21.26) (MEROPS ID: S09.001)antiamnestic172.0730172.1690
113492VY(195–196)ACE inhibitor from sakeInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.1310280.3030
124005RA(135–136)Activation of ubiquitin-dependent proteolysisactivating ubiquitin-mediated proteolysis245.1380245.2670
134005RA(193–194)Activation of ubiquitin-dependent proteolysisactivating ubiquitin-mediated proteolysis245.1380245.2670
147513PL(106–107)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
157558VK(17–18)ACE inhibitor from buckwheatACE inhibitor245.1620245.3070
167562IA(100–101)ACE inhibitor from soy hydrolysateACE inhibitor202.1210202.2390
177588RA(135–136)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor245.1380245.2670
187588RA(193–194)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor245.1380245.2670
197594VG(11–12)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
207594VG(125–126)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor174.0890174.1850
217625PG(46–47)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor172.0730172.1690
227827IE(89–90)ACE inhibitorACE inhibitor260.1260260.2760
237829VE(161–162)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor246.1100246.2490
248224VY(195–196)antioxidative peptidefree radical scavengingantioxidative280.1310280.3030
258323IL(36–37)Glucose uptake stimulating peptideGlucose uptake stimulatingstimulating244.1680244.3200
268525IA(100–101)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor202.1210202.2390
278526RA(135–136)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1380245.2670
288526RA(193–194)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1380245.2670
298560SL(78–79)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor218.1160218.2400
308638PL(106–107)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
318685WT(68–69)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor305.1260305.3180
328802IL(36–37)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor244.1680244.3200
338805IQ(159–160)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor259.1420259.2910
348855PG(46–47)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor172.0730172.1690
358858PK(180–181)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor243.1460243.2910
368882RG(200–201)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor231.1220231.2400
378886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
388886RL(165–166)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
398894SK(149–150)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor233.1260233.2540
408916VE(161–162)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor246.1100246.2490
418917VF(128–129)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor264.1360264.3100
428918VG(11–12)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
438918VG(125–126)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor174.0890174.1850
448921VK(17–18)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor245.1620245.3070
458927VT(115–116)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor218.1150218.2380
468929VY(195–196)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor280.1310280.3030
479079IL(36–37)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor244.1680244.3200
Table A50. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using pepsin (pH >2).
Table A50. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage carried out by using pepsin (pH >2).
DHt (%)
70.7317
No.ActivityAEWBEV
1regulating0.00490.33560
2dipeptidyl peptidase IV inhibitor0.11650.17919.8559287499226E-50.45689549540936
3ACE inhibitor0.07770.13340.0022157552830350.082804687193409
4antithrombotic0.00490.50520
5antiamnestic0.00490.50520
6activating ubiquitin-mediated proteolysis0.00970.66440
7antioxidative0.00490.067300
8stimulating0.00490.14410
Table A51. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using cocolysin.
Table A51. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using cocolysin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13522IPP(144–146)ACE inhibitor (from bovine b-CN)ACE inhibitor325.1880325.3940
23666YP(105–106)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor278.1150278.2870
37600AG(53–54)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor146.0580146.1310
47605FG(129–130)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
57619LG(182–183)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
67697YK(20–21)ACE inhibitor from wakameACE inhibitor309.1570309.3440
78521YP(105–106)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor278.1150278.2870
88760AG(53–54)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor146.0580146.1310
98764AV(56–57)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
108764AV(194–195)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
118779FQ(13–14)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor293.1260293.3080
128824LT(22–23)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor232.1310232.2650
138937YH(87–88)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor318.1210318.3120
148939YK(20–21)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor309.1570309.3440
158946YV(102–103)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor280.1310280.3030
168951AV(56–57)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
178951AV(194–195)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
189076FQ(13–14)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor293.1260293.3080
199077YV(102–103)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.1310280.3030
209087YH(87–88)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor318.1210318.3120
219213LR(134–135)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor287.1850287.3480
229213LR(137–138)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor287.1850287.3480
239213LR(142–143)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor287.1850287.3480
Table A52. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using cocolysin.
Table A52. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using cocolysin.
DHt (%)
30.2439
No.ActivityAEWBEV
1ACE inhibitor0.06800.11670.00214105627429610.080013120769247
2dipeptidyl peptidase IV inhibitor0.04370.06721.5313466662583E-60.0070989290961449
Table A53. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using subtilisin.
Table A53. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using subtilisin.
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
13257RL(138–139)beta-lactokininInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor287.1850287.3480
23384VF(128–129)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor264.1360264.3100
33486VW(71–72)ACE inhibitor from sake leesInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor303.1470303.3460
43492VY(195–196)ACE inhibitor from sakeInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.1310280.3030
53546VAY(103–105)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor351.1680351.3820
67513PL(106–107)ACE inhibitor from Alaskan pollack skinInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor228.1360228.2770
77591GF(130–131)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor222.0890222.2290
87599GL(183–184)ACE inhibitorInhibitor of Angiotensin-converting enzyme (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor188.1050188.2120
97693KL(21–22)ACE inhibitor from wakameACE inhibitor259.1780259.3340
108219TY(23–24)antioxidative peptideantioxidative282.1100282.2750
118224VY(195–196)antioxidative peptidefree radical scavengingantioxidative280.1310280.3030
128461VW(71–72)Antioxidant peptide from marine bivalve (Mactra veneriformis)Antioxidantantioxidative303.1470303.3460
138561GL(183–184)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor188.1050188.2120
148638PL(106–107)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor228.1360228.2770
158782GF(130–131)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor222.0890222.2290
168886RL(138–139)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor287.1850287.3480
178910TS(77–78)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor206.0790206.1850
188910TS(120–121)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor206.0790206.1850
198911TT(69–70)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor220.0940220.2100
208914TY(23–24)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor282.1100282.2750
218917VF(128–129)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor264.1360264.3100
228926VS(42–43)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor204.1000204.2130
238928VW(71–72)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor303.1470303.3460
248929VY(195–196)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor280.1310280.3030
259071IAY(100–102)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: M02-001)ACE inhibitor365.1840365.4090
269074DF(204–205)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor280.0949280.2660
Table A54. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using subtilisin.
Table A54. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using subtilisin.
DHt (%)
29.2683
No.ActivityAEWBEV
1ACE inhibitor0.05340.09170.00550383876283080.20568320455268
2antioxidative0.01460.200500
3dipeptidyl peptidase IV inhibitor0.05830.08961.8563339357632E-60.0086054864513139
Table A55. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using V-8 protease (Glutamyl endopeptidase).
Table A55. Bioactive peptides from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using V-8 protease (Glutamyl endopeptidase).
No.Peptide IDSequenceLocationNameFunctionActivityMonoisotopic MassChemical Mass
18898TD(34–35)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor234.0739234.1940
28934YE(29–30)dipeptidyl peptidase IV inhibitor (DPP IV inhibitor)Inhibitor of Dipeptidyl Peptidase IV (EC 3.4.14.5) (MEROPS ID: S09.003)dipeptidyl peptidase IV inhibitor310.1050310.2860
39078YE(29–30)ACE inhibitorInhibitor of Angiotensin-Converting Enzyme (ACE) (EC 3.4.15.1) (MEROPS ID: XM02-001)ACE inhibitor310.1050310.2860
Table A56. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using V-8 protease (Glutamyl endopeptidase).
Table A56. AE, DHt, W, BE and V values from RubisCO of Halophila stipulacea. In silico enzymatic cleavage was carried out by using V-8 protease (Glutamyl endopeptidase).
DHt (%)
11.7073
No.ActivityAEWBEV
1dipeptidyl peptidase IV inhibitor0.00970.014900
2ACE inhibitor0.00490.00847.6943555746376E-60.0002875447082947

References

  1. Lipkin, Y. Halophila stipulacea, a review of a successful immigration. Aquat. Bot. 1975, 1, 203–215. [Google Scholar] [CrossRef]
  2. Fritsch, C. Uber die Auffindung einer marinen Hydrocharidee im Mittelmeer. Verh. Zool. Bot. Ges. Wien 1895, 45, 104–106. [Google Scholar]
  3. Guiry, M.D.; Guiry, G.M. AlgaeBase. World-wide electronic publication, National University of Ireland, Galway. Available online: http://www.algaebase.org (accessed on 3 February 2018).
  4. Duarte, C. The future of seagrass meadows. Environ. Conserv. 2002, 29, 129–206. [Google Scholar] [CrossRef]
  5. Willette, D.A.; Ambrose, R.F. Effects of the invasive seagrass Halophila stipulacea on the native seagrass, Syringodium filiforme, and associated fish and epibiota communities in the Eastern Caribbean. Aquat. Bot. 2012, 103, 74–82. [Google Scholar] [CrossRef]
  6. Van Tussenbroek, B.I.; Van Katwijk, M.M.; Bouma, T.J.; Van der Heide, T.; Govers, L.L.; Leuven, R.S.E.W. Non-native seagrass Halophila stipulacea forms dense mats under eutrophic conditions in the Caribbean. J. Sea Res. 2016, 115, 1–5. [Google Scholar] [CrossRef]
  7. Cavas, L.; Pohnert, G. The potential of Caulerpa spp. for biotechnological and pharmacological applications. In Seaweeds and Their Role in Globally Changing Environments; Seckbach, J., Einav, R., Israel, A., Eds.; Springer: Berlin, Germany, 2010; pp. 385–397. ISBN 978-90-481-8568-9. [Google Scholar]
  8. Mollo, E.; Cimino, G.; Ghiselin, M.T. Alien biomolecules: A new challenge for natural product chemists. Biol. Invasions 2015, 17, 941–950. [Google Scholar] [CrossRef]
  9. Hartmann, E.M.; Durighello, E.; Pible, O.; Nogales, B.; Beltrametti, F.; Bosch, R.; Christie-Oleza, J.A.; Armengaud, J. Proteomics meets blue biotechnology: A wealth of novelties and opportunities. Mar. Genom. 2014, 17, 35–42. [Google Scholar] [CrossRef]
  10. Tu, M.; Cheng, S.; Lu, W.; Du, M. Advancement and prospects of bioinformatics analysis for studying bioactive peptides from food-derived protein: Sequence, structure, and functions. TrAC Trends Anal. Chem. 2018, 105, 7–17. [Google Scholar] [CrossRef]
  11. Sánchez, A.; Vázquez, A. Bioactive peptides: A review. Food Qual. Saf. 2017, 1, 29–46. [Google Scholar] [CrossRef]
  12. Minkiewicz, P.; Dziuba, J.; Iwaniak, A.; Dziuba, M.; Darewicz, M. BIOPEP database and other programs for processing bioactive peptide sequences. J. AOAC Int. 2008, 91, 965–980. [Google Scholar]
  13. Agirbasli, Z.; Cavas, L. In silico evaluation of bioactive peptides from the green algae Caulerpa. J. Appl. Phycol. 2017, 29, 1635–1646. [Google Scholar] [CrossRef]
  14. Admassu, H.; Gasmalla, M.A.; Yang, R.; Zhao, W. Bioactive Peptides Derived from Seaweed Protein and Their Health Benefits: Antihypertensive, Antioxidant, and Antidiabetic Properties. J. Food Sci. 2018, 83, 6–16. [Google Scholar] [CrossRef] [PubMed]
  15. Barbosa, E.A.; Oliveira, A.; Plácido, A.; Socodato, R.; Portugal, C.C.; Mafud, A.C.; Ombredane, A.S.; Moreira, D.C.; Vale, N.; Bessa, L.J.; et al. Structure and function of a novel antioxidant peptide from the skin of tropical frogs. Free Radic. Biol. Med. 2018, 115, 68–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Ji, C.; Han, J.; Zhang, J.; Hu, J.; Fu, Y.; Qi, H.; Yu, C. Omics-prediction of bioactive peptides from the edible cyanobacterium Arthrospira platensis proteome. J. Sci. Food Agric. 2018, 98, 984–990. [Google Scholar] [CrossRef] [PubMed]
  17. Wang, Z.; Cui, Y.; Liu, P.; Zhao, Y.; Wang, L.; Liu, Y.; Xie, J. Small Peptides Isolated from Enzymatic Hydrolyzate of Fermented Soybean Meal Promote Endothelium-Independent Vasorelaxation and ACE Inhibition. J. Agric. Food Chem. 2017, 65, 10844–10850. [Google Scholar] [CrossRef] [PubMed]
  18. Zhao, Y.; Li, B.; Dong, S.; Liu, Z.; Zhao, X.; Wang, J.; Zeng, M. A novel ACE inhibitory peptide isolated from Acaudina molpadioidea hydrolysate. Peptides 2009, 30, 1028–1033. [Google Scholar] [CrossRef]
  19. Udenigwe, C.C.; Gong, M.; Wu, S. In silico analysis of the large and small subunits of cereal RubisCO as precursors of cryptic bioactive peptides. Process Biochem. 2013, 48, 1794–1799. [Google Scholar] [CrossRef]
  20. Nielsen, S.D.; Beverly, R.L.; Qu, Y.; Dallas, D.C. Milk bioactive peptide database: A comprehensive database of milk protein-derived bioactive peptides and novel visualization. Food Chem. 2017, 232, 673–682. [Google Scholar] [CrossRef]
  21. Daliry, E.B.M.; Oh, D.H.; Lee, B.H. Bioactive peptides. Foods 2017, 6, 32. [Google Scholar] [CrossRef]
  22. Guan, H.; Diao, X.; Jiang, F.; Han, J.; Kong, B. The enzymatic hydrolysis of soy protein isolate by Corolase PP under high hydrostatic pressure and its effect on bioactivity and characteristics of hydrolysates. Food Chem. 2018, 245, 89–96. [Google Scholar] [CrossRef]
  23. Borgia, J.A.; Fields, G.B. Chemical synthesis of proteins. Trends Biotechnol. 2000, 18, 243–251. [Google Scholar] [CrossRef]
  24. Brown, L.; Pingitore, E.V.; Mozzi, F.; Saavedra, L.M.; Villegas, J.; Hebert, E. Lactic acid bacteria as cell factories for the generation of bioactive peptides. Protein Pept. Lett. 2017, 24, 146–155. [Google Scholar] [CrossRef] [PubMed]
  25. Agrawal, H.; Joshi, R.; Gupta, M. Isolation and characterisation of enzymatic hydrolysed peptides with antioxidant activities from green tender sorghum. LWT Food Sci. Technol. 2017, 84, 608–616. [Google Scholar] [CrossRef]
  26. Wang, Z.; Zhang, X. Isolation and identification of anti-proliferative peptides from Spirulina platensis using three-step hydrolysis. J. Sci. Food Agric. 2017, 97, 918–922. [Google Scholar] [CrossRef] [PubMed]
  27. Connolly, A.; O’keeffe, M.B.; Nongonierma, A.B.; Piggott, C.O.; FitzGerald, R.J. Isolation of peptides from a novel brewers spent grain protein isolate with potential to modulate glycaemic response. Int. J. Food Sci. Technol. 2017, 52, 146–153. [Google Scholar] [CrossRef]
  28. Wang, G.; Li, X.; Wang, Z. APD3: The antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 2016, 44, D1087–D1093. [Google Scholar] [CrossRef]
  29. Shtatland, T.; Guettler, D.; Kossodo, M.; Pivovarov, M.; Weissleder, R. PepBank-a database of peptides based on sequence text mining and public peptide data sources. BMC Bioinform. 2007, 8, 280. [Google Scholar] [CrossRef]
  30. Udenigwe, C.C.; Okolie, C.L.; Qian, H.; Ohanenye, I.C.; Agyei, D.; Aluko, R.E. Ribulose-1, 5-bisphosphate carboxylase as a sustainable and promising plant source of bioactive peptides for food applications. Trends Food Sci. Tech. 2017, 69, 74–82. [Google Scholar] [CrossRef]
  31. Trovaslet, M.; Kapel, R.; Ravallec-Plé, R.; Mouni, F.; Clarisse, M.; Faille, C.; Dhulster, P.; Guillochon, D.; Vercaigne-Marko, D. Secretagogue and bacteriostatic active fractions derived from a peptic hydro-lysate of alfalfa RubisCO small purified subunit. J. Sci. Food Agric. 2007, 87, 534–540. [Google Scholar] [CrossRef]
  32. Je, J.Y.; Cho, Y.S.; Gong, M.; Udenigwe, C.C. Dipeptide Phe-Cys derived from in silico thermolysin-hydrolysed RubisCO large subunit suppresses oxidative stress in cultured human hepatocytes. Food Chem. 2015, 171, 287–291. [Google Scholar] [CrossRef]
  33. Bitam, F.; Ciavatta, M.L.; Carbone, M.; Manzo, E.; Mollo, E.; Gavagnin, M. Chemical analysis of flavonoid constituents of the seagrass Halophila stipulacea: First finding of malonylated derivatives in marine phanerogams. Biochem. Syst. Ecol. 2010, 38, 686–690. [Google Scholar] [CrossRef]
  34. Artimo, P.; Jonnalagedda, M.; Arnold, K.; Baratin, D.; Csardi, G.; de Castro, E.; Duvaud, S.; Flegel, V.; Fortier, A.; Gasteiger, E.; et al. ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 2012, 40, W597–W603. [Google Scholar] [CrossRef] [PubMed]
  35. Dziuba, J.; Iwaniak, A.; Minkiewicz, P. Computer-aided characteristics of proteins as potential precursors of bioactive peptides. Polimery 2003, 48, 50–53. [Google Scholar] [CrossRef] [Green Version]
  36. Minkiewicz, P.; Dziuba, J.; Michalska, J. Bovine meat proteins as potential precursors of biologically active peptides-a computational study based on the BIOPEP database. Food Sci. Technol. Int. 2011, 17, 39–45. [Google Scholar] [CrossRef] [PubMed]
  37. Gasteiger, E.; Hoogland, C.; Gattiker, A.; Duvaud, S.; Wilkins, M.R.; Appel, R.D.; Bairoch, A. Protein identification and analysis tools on the ExPASy server. In the Proteomics Protocols Handbook; Walker, J.M., Ed.; Humana Press Inc.: Totowa, NJ, USA, 2005; pp. 571–607. [Google Scholar]
  38. Expasy. Available online: https://web.expasy.org/protparam/ (accessed on 8 January 2018).
  39. Verdecchia, P.; Angeli, F.; Mazzotta, G.; Gentile, G.; Reboldi, G. The renin angiotensin system in the development of cardiovascular disease: Role of aliskiren in risk reduction. Vasc. Health Risk Manag. 2008, 4, 971. [Google Scholar] [CrossRef] [PubMed]
  40. Lin, H.C.; Chou, S.T.; Chuang, M.Y.; Liao, T.Y.; Tsai, W.S.; Chiu, T.H. The effects of Caulerpa microphysa enzyme-digested extracts on ACE-inhibitory activity and in vitro anti-tumour properties. Food Chem. 2012, 134, 2235–2241. [Google Scholar] [CrossRef] [PubMed]
  41. Sarmadi, B.H.; Ismail, A. Antioxidative peptides from food proteins: A review. Peptides 2010, 31, 1949–1956. [Google Scholar] [CrossRef] [PubMed]
  42. Barnett, A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract. 2006, 60, 1454–1470. [Google Scholar] [CrossRef]
  43. Cheon, S.; Dean, M.; Chahrour, M. The ubiquitin proteasome pathway in neuropsychiatric disorders. Neurobiol. Learn. Mem. 2018. [Google Scholar] [CrossRef]
  44. Layfield, R.; Cavey, J.R.; Lowe, J. Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res. Rev. 2003, 2, 343–356. [Google Scholar] [CrossRef]
  45. Zenezini Chiozzi, R.; Capriotti, A.L.; Cavaliere, C.; La Barbera, G.; Piovesana, S.; Samperi, R.; Lagana, A. Purification and identification of endogenous antioxidant and ACE-inhibitory peptides from donkey milk by multidimentional liquid chromatography and nano HPLC-high resolution mass spectrometry. Anal. Bioanal. Chem. 2016, 408, 5657–5666. [Google Scholar] [CrossRef] [PubMed]
  46. Tu, M.; Feng, L.; Wang, Z.; Qiao, M.; Shahidi, F.; Lu, W.; Du, M. Sequence analysis and molecular docking of antithrombotic peptides from casein hydrolysate by trypsin digestion. J. Funct. Foods 2017, 32, 313–323. [Google Scholar] [CrossRef]
  47. Tu, M.; Wang, C.; Chen, C.; Zhang, R.; Liu, H.; Lu, W.; Jiang, L.; Du, M. Identification of a novel ACE-inhibitory peptide from casein and evaluation of the inhibitory mechanisms. Food Chem. 2018, 256, 98–104. [Google Scholar] [CrossRef] [PubMed]
  48. Lafarga, T.; O’Connor, P.; Hayes, M. Identification of novel dipeptidyl peptidase-IV and angiotensin-I-converting enzyme inhibitory peptides from meat proteins using in silico analysis. Peptides 2014, 59, 53–62. [Google Scholar] [CrossRef] [PubMed]
  49. Sayd, T.; Dufour, C.; Chambon, C.; Buffière, C.; Remond, D.; Santé-Lhoutellier, V. Combined in vivo and in silico approaches for predicting the release of bioactive peptides from meat digestion. Food Chem. 2018, 249, 111–118. [Google Scholar] [CrossRef] [PubMed]
  50. Stephany, R.W. Hormones in meat: Different approaches in the EU and in the USA. Apmis 2001, 109, S357–S363. [Google Scholar] [CrossRef]
Table 1. The values of the parameters describing the predicted efficiency of bioactive Angiotensin Converting Enzyme (ACE) inhibitor fragment release from Halophila stipulacea-RubisCO by proteases.
Table 1. The values of the parameters describing the predicted efficiency of bioactive Angiotensin Converting Enzyme (ACE) inhibitor fragment release from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Chymotrypsin A0.58220.04850.08330.00170.0645
Trypsin0.58080.00970.01670.00000.0004
Pepsin0.58260.01940.03330.00000.0009
Proteinase K0.58250.07770.13340.00330.1240
Pancreatic elestase0.58270.04370.07500.00070.0256
V-protease0.58330.00490.00840.00000.0003
Thermolysin0.58250.07770.13340.00520.1932
Chymotrypsin C0.58260.06310.10830.00180.0671
Plasmin0.58080.00970.01670.00000.0004
Cathepsin G0.58260.03880.06660.00080.0308
Chymase0.58260.03880.06660.00080.0308
Papain0.58260.06310.10830.00190.0718
Ficin0.58270.06800.11670.00160.0592
Leukocyte elastase0.58220.04850.08330.00250.0916
Metridin0.58260.03880.06660.00080.0308
Pancreatic elastase II0.58260.01940.03330.00000.0009
Bromelain0.58220.03400.05840.00070.0276
Oligopeptidase B0.58080.00970.01670.00000.0004
Calpain 20.58270.08740.15000.00340.1285
Glycyl endopeptidase0.58330.00490.00840.00000.0002
Oligopeptidase F0.58260.01940.03330.00000.0009
Proteinase P1 (lactocepin)0.58270.02430.04170.00050.0198
Pepsin (pH > 2)0.58250.07770.13340.00220.0828
Coccolysin0.58270.06800.11670.00210.0800
Subtilisin0.58230.05340.09170.00550.2057
V-8 protease (Glutamyl endopeptidase, pH:7.8)0.58330.00490.00840.00000.0003
Table 2. The values of parameters describing the predicted efficiency of release of the bioactive antioxidative fragment from Halophila stipulacea-RubisCO by proteases.
Table 2. The values of parameters describing the predicted efficiency of release of the bioactive antioxidative fragment from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Chymotrypsin A0.07280.00490.067300
Proteinase K0.07280.02430.333800
Chymotrypsin C0.07280.00970.133200
Cathepsin0.07280.00490.067300
Chymase0.07280.00490.067300
Papain0.07280.00490.067300
Ficin0.07280.00490.067300
Leukocyte elastase0.07280.00490.067300
Metridin0.07280.00490.067300
Bromelain0.07280.00490.067300
Calpain 20.07280.00970.133200
Proteinase P1 (lactocepin)0.07280.00970.133200
Pepsin (pH > 2)0.07280.00490.067300
Pubtilisin0.07280.01460.200500
Table 3. The values of parameters describing the predicted efficiency of release of bioactive dipeptidyl peptidase IV inhibitor fragment from Halophila stipulacea-RubisCO by proteases.
Table 3. The values of parameters describing the predicted efficiency of release of bioactive dipeptidyl peptidase IV inhibitor fragment from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Chymotrypsin A0.65010.03400.05230.00000.0086
Trypsin0.65180.01460.02240.00000.0000
Pepsin0.65180.01460.02240.00000.0086
Proteinase K0.65070.09220.14170.00000.0345
Pancreatic elestase0.65080.07770.11940.00000.0969
Prolyl oligopeptidase0.65330.00490.00750.00000.0000
V-protease0.65330.00490.00750.00000.0000
Thermolysin0.65040.05340.08210.00000.0071
Chymotrypsin C0.65010.04850.07460.00000.0242
Plasmin0.65180.01460.02240.00000.0000
Cathepsin0.64970.02430.03740.00000.0086
Clostripain0.65330.00490.00750.00000.0000
Chymase0.64970.02430.03740.00000.0086
Papain0.65060.08250.12680.00000.1066
Ficin0.65030.08740.13440.00000.0510
Leukocyte elastase0.65060.07280.11190.00000.1056
Metridin0.64970.02430.03740.00000.0086
Pancreatic elastase II0.65180.01460.02240.00000.0086
Bromelain0.65070.06800.10450.00000.1005
Oligopeptidase B0.65180.01460.02240.00000.0000
Calpain 20.65060.12140.18660.00000.1066
Glycyl endopeptidase0.65330.00490.00750.00000.0000
Oligopeptidase F0.65180.01460.02240.00000.0086
Proteinase P1 (lactocepin)0.65010.03400.05230.00000.0000
Pepsin (pH > 2)0.65050.11650.17910.00010.4569
Cocolysin0.65030.04370.06720.00000.0071
Subtilisin0.65070.05830.08960.00000.0086
V-8 protease (Glutamyl endopeptidase)0.65100.00970.01490.00000.0000
Table 4. The values of parameters describing the predicted efficiency of release of bioactive activating ubiquitin-mediated proteolysis fragment from Halophila stipulacea-RubisCO by proteases.
Table 4. The values of parameters describing the predicted efficiency of release of bioactive activating ubiquitin-mediated proteolysis fragment from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Pancreatic elastase0.01460.00970.66440-
Leukocyte elastase0.01460.00490.33560-
Proteinase P1 (lactocepin)0.01460.00490.33560-
Pepsin (pH > 2)0.01460.00970.66440-
Table 5. The values of parameters describing the predicted efficiency of the release of bioactive regulating fragment from Halophila stipulacea-RubisCO by proteases.
Table 5. The values of parameters describing the predicted efficiency of the release of bioactive regulating fragment from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Chymotrypsin C0.01460.00490.33560-
Ficin0.01460.00490.33560-
Calpain 20.01460.00490.33560-
Pepsin (pH > 2)0.01460.00490.33560-
Table 6. The values of parameters describing the predicted efficiency of release of bioactive antithrombotic fragment from Halophila stipulacea-RubisCO by proteases.
Table 6. The values of parameters describing the predicted efficiency of release of bioactive antithrombotic fragment from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Chymotrypsin C0.00970.00490.50520-
Calpain 20.00970.00490.50520-
Pepsin (pH > 2)0.00970.00490.50520-
Table 7. The values of parameters describing the predicted efficiency of release of bioactive antiamnestic fragment from Halophila stipulacea-RubisCO by proteases.
Table 7. The values of parameters describing the predicted efficiency of release of bioactive antiamnestic fragment from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Chymotrypsin C0.00970.00490.50520-
Calpain 20.00970.00490.50520-
Pepsin (pH > 2)0.00970.00490.50520-
Table 8. The values of parameters describing the predicted efficiency of release of bioactive stimulating fragment from Halophila stipulacea-RubisCO by proteases.
Table 8. The values of parameters describing the predicted efficiency of release of bioactive stimulating fragment from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Papain0.03400.00490.14410-
Pepsin (pH > 2)0.03400.00490.14410-
Table 9. The values of parameters describing the predicted efficiency of release of bioactive immunomodulating fragment from Halophila stipulacea-RubisCO by proteases.
Table 9. The values of parameters describing the predicted efficiency of release of bioactive immunomodulating fragment from Halophila stipulacea-RubisCO by proteases.
ProteasesAAEWBV
Calpain 20.00970.00490.505200
Table 10. Theoretical degree of hydrolysis (DHt) values for the following enzymes.
Table 10. Theoretical degree of hydrolysis (DHt) values for the following enzymes.
ProteasesDHt
Chymotrypsin A23.4146
Trypsin10.7317
Pepsin12.1951
Proteinase K37.0732
Pancreatic elastase54.6341
Prolyl oligopeptidase6.8293
V-protease7.3171
Thermolysin36.5854
Chymotrypsin C35.6098
Plasmin10.7317
Cathepsin20.4878
Clostripain5.3659
Chymase19.5122
Papain43.4146
Ficin44.3902
Leukocyte elastase38.5366
Metridin19.5122
Thrombin0
Pancreatic elastase II13.1707
Bromelain54.1463
Endopeptidase II0
Oligopeptidase B10.7317
Calpain 247.3171
Glycyl endopeptidase9.7561
Oligopeptidase F12.1951
Proteinase P1 (lactocepin)41.4634
Xaa-Pro dipeptidase0
Pepsin (pH>2)70.7317
Cocolysin30.2439
Subtilisin29.2683
Chymosin0
Ginger protease (zingipain)0
V-8 protease (Glutamyl endopeptidase)11.7073

Share and Cite

MDPI and ACS Style

Kandemir-Cavas, C.; Pérez-Sanchez, H.; Mert-Ozupek, N.; Cavas, L. In Silico Analysis of Bioactive Peptides in Invasive Sea Grass Halophila stipulacea. Cells 2019, 8, 557. https://doi.org/10.3390/cells8060557

AMA Style

Kandemir-Cavas C, Pérez-Sanchez H, Mert-Ozupek N, Cavas L. In Silico Analysis of Bioactive Peptides in Invasive Sea Grass Halophila stipulacea. Cells. 2019; 8(6):557. https://doi.org/10.3390/cells8060557

Chicago/Turabian Style

Kandemir-Cavas, Cagin, Horacio Pérez-Sanchez, Nazli Mert-Ozupek, and Levent Cavas. 2019. "In Silico Analysis of Bioactive Peptides in Invasive Sea Grass Halophila stipulacea" Cells 8, no. 6: 557. https://doi.org/10.3390/cells8060557

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop